GlaxoSmithKline has agreed to pay $105m to more than 40 US states to settle allegations of unlawful marketing, ending a long saga in which the UK company was accused of providing lavish incentives for salesmen and doctors to promote its drugs for unauthorised purposes.
英國制藥集團葛蘭素史克(GlaxoSmithKline，簡稱：GSK)已同意向美國40多個州支付1.05億美元，以了結對其非法營銷的指控，從而結束了一場曠日持久的訴訟戰，GSK被控向銷售人員和醫生提供慷慨的激勵舉措，以推銷其藥物用于未經批準的用途。
您已閱讀13%（393字），剩余87%（2522字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。